source
- Alkermes' narcolepsy Phase 3 success; Boehringer's antibody dealPlus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. 😴 Alkermes’ narcolepsy drug succeeds in Phase 3 study: The company’s drug Lumryz, approved in 2023 for narcoleps…Endpoints · 3mo ago↗ source
- STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and moreThe 17 pharmaceutical companies anchoring TrumpRx poured more than $130 million into federal lobbying in 2025 — a nearly 23% surgeSTAT · 3mo ago↗ source
- FDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADAFDA continues to implement its bold food agenda, with two decisive actions focused on food chemical safety.fda press